Alzheimer's disease (AD) is thought to be caused by the accumulation of amyloid beta (A␤) peptide within the brain. Endothelin-converting enzyme-2 (ECE-2), which is expressed in neural tissues, cleaves 'big endothelin' to produce the vasoconstrictor endothelin-1. ECE-2 also degrades A␤. We have examined ECE-2 expression in the temporal cortex of brain tissue from patients with AD, vascular dementia, and controls. Immunohistochemistry with specific antibodies showed ECE-2 to be abundant within pyramidal neurons in both the hippocampus and neocortex, but also to be present in certain astrocytes and microglia, particularly in AD brains. Quantitative real-time PCR showed ECE-2 mRNA to be markedly elevated in AD but not in vascular dementia. ECE-2 protein concentration, measured by sandwich enzyme-linked immunosorbent assay, was also significantly elevated in AD but not in vascular dementia. Exposure of SH-SY5Y human neuroblastoma cells to monomeric or oligomeric A␤ 1-42 caused an initial decrease in ECE-2 mRNA at 4 hours, but a marked increase by 24 hours. Our findings indicate that A␤ accumulation in AD is unlikely to be caused by ECE-2 deficiency. However, ECE-2 expression is up-regulated, perhaps to minimize A␤ accumulation, but this may also be a mechanism through which endothelin-1 production is increased and cerebral blood flow is reduced in AD. Our findings suggest that endothelin-1 receptor antagonists, already licensed for treating other diseases, could be of benefit in AD therapies. 
balance between its production and clearance. Familial autosomal dominant forms of AD, which either increase overall production of A␤ or the ratio of A␤ to A␤ , account for fewer than 5% of cases. The mechanisms by which A␤ accumulates in late-onset sporadic AD, the major form of the disease, are unknown. There is little evidence of increased A␤ production in late-onset sporadic AD, except perhaps in the later stages of disease, when ␤-site APP-cleaving enzyme (BACE) activity may be increased. 2, 3 The initiating abnormality and perhaps the main cause of A␤ accumulation in late-onset sporadic AD seems to be an impairment of A␤ clearance. Several potential pathways of A␤ clearance have been identified. These include perivascular drainage, 4, 5 receptor-mediated transport across the blood-brain barrier, 6, 7 and proteolytic degradation of A␤ within the brain. 8 -10 The endothelin-converting enzymes (ECEs) are a class of type II integral membrane-bound proteases, belonging to the M13 family of zinc metallopeptidases. The ECEs are named for their ability to convert the inactive precursor 'big endothelin' to its potent vasoactive peptide endothelin-1 (ET-1). In addition, ECEs have been reported to hydrolyze several biologically active peptides in vitro, including bradykinin, neurotensin, substance P, and oxidized insulin B chain, by cleavage on the amino side of hydrophobic residues, 11, 12 and have been shown to degrade A␤. 13 The two ECE isoforms, ECE-1 and ECE-2, have 59% sequence homology and similar catalytic activity; however, in contrast to the neutral pH optimum of ECE-1, ECE-2 has an pH optimum of pH 5.5 and is active within a narrow pH range.
14 Neural tissues are the most abundant site of ECE-2 expression.
14 ECE-2 has been localized to intracellular secretory compartments. 15 With a pH 5.5 optimum, a predominantly neural distribution and very little expression in peripheral tissues, ECE-2 is thought to have a role in the non-classical processing of regulatory peptides. 16 ECE-2 homozygous knock-out mice 17 show decreased degradation of A␤ and significantly elevated levels of A␤ and A␤ in the brain. 18 ECE-2 knock-out mice are deficient in learning and memory, without having impaired balance or motor function. 19 Although these studies suggest that ECE-2 is a physiologically relevant A␤-degrading enzyme with a role in learning and memory, little information is available on ECE-2 expression in AD: to our knowledge only a single report has been made of decreased ECE-2 mRNA levels in the inferior part of the parietal lobe, in six cases of AD. 20 Our aim in the present study was to investigate the distribution of ECE-2, and the levels of ECE-2 mRNA and protein in the temporal neocortex of AD and non-demented control brains. Because ECE-2 activity leads to the production of the vasoconstrictor peptide ET-1, we thought it would be of interest to measure ECE-2 mRNA and protein levels in vascular dementia (VaD) too. Finally we also examined the relationship between A␤ exposure and ECE-2 expression in SH-SY5Y neuroblastoma cells in vitro.
Materials and Methods

Study Cohort
We studied brain tissue from 14 cases of neuropathologically confirmed sporadic AD, 15 matched controls and 15 cases of VaD (Table 1 ). The tissue was obtained from the Human Tissue Authority licensed South West Dementia Brain Bank, University of Bristol. The brains had been divided midsagittally at autopsy: the left half was sliced and frozen at Ϫ80°C and the right half was fixed in formalin for detailed neuropathological assessment. The AD cases were 57 to 93 years in age (mean 77.8, SD 9) and were selected on the basis of a diagnosis according to the Consortium to Establish a Registry for Alzheimer's Disease of 'definite AD' and a Braak tangle stage of V or VI. 21 The postmortem (PM) delays ranged from 4 to 36 hours (mean 20.5, SD 11.2). The controls were 58 to 93 years in age (mean 78, SD 9.8), had no history of dementia, few or no neuritic plaques, a Braak tangle stage of III or less, and no other neuropathological abnormalities, and had similar PM delays, of 3 to 36 hours (mean 21.3, SD 11.7). The VaD cases had a clinical history of dementia, no more than occasional neuritic plaques, a Braak tangle stage of II or less, histopathological evidence of multiple infarcts/ischemic lesions, moderate to severe atheroma and/or arteriosclerosis, and an absence of histopathological evidence of other disease likely to cause dementia. The VaD cases were 67 to 97 years in age (mean 83.4, SD 7.7) and had PM delays of 20 to 70 hours (mean 42.9, SD 17.4). For ECE-2 protein and mRNA level studies, we dissected samples of unfixed frozen cortex from Brodmann area 22 in the left temporal lobe. For immunohistochemistry, we used formalin-fixed, paraffinembedded tissue from the right temporal lobe. The studies had local Research Ethics Committee approval.
Characterization of ECE-2 Antibodies
We used two antibodies against ECE-2, both provided by R&D Systems (Minneapolis, MN). One was raised in goats against recombinant human ECE-2, amino acids 104 to 787. The other was raised in rats against recombinant human ECE-2, amino acids 104 to 787. We assessed the specificity of these antibodies against fulllength recombinant human ECE-1 and ECE-2 protein (R&D Systems). The recombinant proteins were denatured and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 4% to 20% Tris-HCL precast gels (Bio-Rad Hercules, CA). The proteins were transferred to nitrocellulose membrane (Bio-Rad) overnight at 4°C. The binding of non-specific protein was reduced by blocking with 10% nonfat dry milk in Tris- buffered saline-Tween (0.05%) for 1 hour. The membrane was incubated with each antibody at 1:500 and 1:1000 dilutions in 5% nonfat dry milk/Tris-buffered saline-Tween for 1 hour at room temperature on a shaking platform. The membrane was washed three times in Tris-buffered saline-Tween, incubated with peroxidase-conjugated, species-specific, secondary antibodies (goat, Vector labs, Burlingame, CA; rat, Cell Signaling Technology, Boston, MA) diluted 1:5000 in 5% nonfat dry milk/Tris-buffered saline-Tween for 1 hour at room temperature on a shaking platform, and immunolabeled bands were visualized using enhanced chemiluminescence (ECL Plus kit, Amersham Biosciences, Buckinghamshire, UK). Band density was measured with the aid of Image-J software. Both antibodies detected recombinant ECE-2 at the anticipated size. The goat antibody showed ϳ5% cross-reactivity to ECE-1. The rat antibody showed no cross-reactivity to ECE-1.
Immunoperoxidase Staining of Paraffin Sections
Paraffin sections 7 m in thickness were cut through temporal lobe in the coronal plane of the lateral geniculate body. These sections were collected on 3-aminopropyl-triethoxy-silane coated slides and left to dry overnight in a 40°C oven. Before staining, slides were incubated overnight in a 60°C oven, dewaxed, and rehydrated through graded alcohols. Endogenous peroxidase was blocked by incubation with 3% hydrogen peroxide in methanol for 30 to 45 minutes, followed by a 10 minutes wash in running water. Sections were microwaved in citrate buffer (9 mmol/L tri-sodium citrate, pH 6.0) until boiling, left to cool for 5 minutes, microwaved again until boiling, and left to cool for 15 minutes before being washed in continuously running water for 10 minutes and rinsed in PBS. Non-specific binding of antibody was blocked by incubation of the sections in 20% normal goat serum (Vector labs) for 20 minutes before application of antibody to ECE-2 (rat, 1:200, R&D Systems) overnight at room temperature. Sections were washed in two changes of PBS and biotinylated Universal Antibody (Vector labs) applied for 20 minutes. Sections were washed in two changes of PBS, then VectaElite ABC complex (Vector labs), which had been prepared and left to sit at room temperature for 30 minutes, was applied for 20 minutes. Sections were washed in two changes of PBS, incubated for 7 to 10 minutes in 3,3Ј-diaminobenzidine containing Ͻ0.1% H 2 O 2 (Vector labs) and washed in continuously running water for 10 minutes. Sections were immersed in copper sulfate for 4 minutes, washed in running water, counterstained with Harris' hematoxylin, and washed in running water for at least 10 minutes, before being dehydrated, cleared, and mounted.
Double Immunoperoxidase Staining of Paraffin Sections
Sections were immunolabeled for ECE-2 with 3,3Ј-diaminobenzidine as described for single immunolabeling. After sections had been immersed in copper sulfate and washed in water, they were again immersed in 3% hydrogen peroxide in methanol for 45 minutes, rinsed for 10 minutes in running water, and incubated in 20% normal goat serum for 20 minutes. Sections were then incubated with antibody either to glial fibrillary acidic protein (1: 1200, Dako, Glostrup, Denmark) or human leukocyte antigen DR-1 (1:800, Dako) overnight at room temperature. Sections were washed in two changes of PBS and biotinylated Universal Antibody (Vector labs) was applied for 20 minutes. Sections were washed in two changes of PBS, then VectaElite ABC complex (Vector labs), which had been prepared and left to sit at room temperature for 30 minutes, was applied for 20 minutes. Sections were washed in two changes of PBS, incubated for 7 to 10 minutes in Vector Very Intense Purple Substrate Kit (Vector labs) and washed in running water for 10 minutes. Sections were immersed in copper sulfate for 4 minutes, washed in running water, counterstained with Harris's hematoxylin, and washed in running water for at least 10 minutes, before being dehydrated, cleared, and mounted.
Assessment of Post-Mortem Stability of ECE-2 Protein in Frozen Brain Tissue
The effects of PM delay were simulated using tissue from a brain removed 5.5 hours after the death of a control patient. A 50 mg sample of anterior frontal cortex was subdivided into 10 aliquots. The individual aliquots were stored for 0, 6, 12, 18, 24, 48, or 72 hours at room temperature, or 24, 48, or 72 hours at 4°C. They were then homogenized in 250 l lysis buffer (0.1 mmol/L NaCl, 10 mmol/L Tris pH 6, 1 mol/L phenylmethylsulphonyl fluoride, 1 g/ml aprotinin, and 1% SDS in distilled water) in a Precellys 24 homogenizer (Stretton Scientific, Stretton, UK) with 2.3-mm silica beads (Biospec, Thistle Scientific, Glasgow, UK). ECE-2 protein levels were measured by sandwich enzyme-linked immunosorbent assay, as described below.
cDNA Generation and Real-Time PCR on Brain Tissue
Brain tissue from the temporal neocortex was homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA), in a Precellys 24 homogenizer (Stretton Scientific). The homogenates were incubated for 3 minutes in chloroform then centrifuged at 12,000 ϫ g for 15 minutes at 4°C. The aqueous phase was mixed with an equal volume of isopropyl alcohol and 30 g of glycogen, incubated for 10 minutes and centrifuged at 12,000 ϫ g for 10 minutes at 4°C to precipitate the RNA. The RNA pellet was washed with 75% ethanol, resuspended in water (Sigma-Aldrich, Gillingham, UK), and treated with DNase-I (40U, Roche Diagnostics Ltd, West Sussex, UK) to remove any DNA. RNA concentration was determined using a Ribogreen RNA quantification kit (Invitrogen) and a fluorescence plate reader (FLUOstar OPTIMA, BMG Labtech, Aylesbury, UK). cDNA was produced using the High Capacity c-DNA Archive Kit from Applied Biosystems (Foster City, CA): 100 ng of RNA in a total volume of 100 l was incubated at 25°C for 10 minutes, 37°C for 2 hours, followed by inactivation at 85°C for 5 seconds. cDNA concentration was determined with the Picogreen DNA quantification kit (Invitrogen, UK). Real-time reverse transcription PCR (RT-PCR) was performed using the ABI 7000 sequencing detection system (ABI Prism, Applied Biosystems) with Assay-on-demand Gene Expression Products for ECE-2, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), microtubule-associated protein-2, and neuron-specific enolase (TaqMan MGB probes, FAM dye-labeled, Applied Biosystems), SensiMix dT (Quantace, London, UK), and 10 ng of cDNA in a total volume of 20 l: 50°C for 2 minutes; 95°C for 10 minutes; and 40 cycles of 95°C for 15 minutes and 60°C for 1 minute. All samples were analyzed in triplicate. Relative gene expression (expressed as fold difference of each subject relative to the average of control tissue) was calculated using the 2
Ϫ⌬⌬Ct method, 22 and the geometric mean taken for each group. Separate calculations were made using GAPDH, microtubule-associated protein-2, or neuron-specific enolase as the reference 'housekeeping' gene.
Measurement of ECE-2 Protein Levels Using Sandwich Enzyme-Linked Immunosorbent Assay
Five hundred milligram samples of temporal neocortex were homogenized in lysis buffer with the aid of a Precellys 24 homogenizer (Stretton Scientific), aliquoted, and stored at Ϫ80°C until required. Total protein concentrations were determined using the Sigma-Aldrich total protein kit according to the manufacturer's instructions; absorbance values were read at 590 nm on a FLUOstar Optima plate reader (BMG Labtech, Aylesbury, UK). Ninety-six-well immunoplates (Nunc Maxisorp, obtained from Fisher Scientific, Loughborough, UK) were coated with a goat anti-human ECE-2 antibody (1:20, R&D Systems) in coating buffer (0.1 M/L sodium carbonate, 0.3 M/L sodium bicarbonate, pH 9.6) and left at 4°C overnight. The wells were drained, washed thoroughly with wash buffer (0.05% Tween20/PBS) and incubated with 300 l blocking buffer (0.5% nonfat dry milk powder in PBS) for 90 minutes at room temperature on a shaking platform. Serial dilutions of recombinant human ECE-2 (R&D Systems) in blocking buffer were used to produce a standard curve with final concentrations ranging from 27 to 432 ng/ml. Homogenates were diluted in 50 l blocking buffer to a final concentration of 1 mg/ml total protein, added in triplicate and left at room temperature for 2 hours while shaking. The plates also included blank wells that contained blocking buffer and lysis buffer without tissue. After further washes, 50 l of rat anti-human ECE-2 (1 g/ml, R&D Systems) in blocking buffer was added to each well and left for 90 minutes at room temperature while shaking. The wells were washed and incubated with 50 l peroxidase anti-rat conjugate (1:500, Cell Signaling Technology) in wash buffer for 60 minutes at room temperature while shaking. Wells were again washed, peroxidase substrate (R&D Systems) added, and plates left to incubate for 20 minutes in the dark before the addition of Stop solution (R&D Systems). Absorbance was read by a plate reader with a 450 nm filter. The mean readings from the blank wells were subtracted from the readings obtained from the wells containing recombinant protein or brain homogenate. A standard curve was generated and ECE-2 protein concentration calculated for each homogenate. Each sample was repeated on two different plates and measured in duplicate on each plate.
Preparation of Monomeric and Oligomeric A␤ 1-42
Lyophilized A␤ (Anaspec, CA) was reconstituted in 35% acetonitrile. This 1.6 mmol/L stock solution of monomeric A␤ 1-42 was diluted to 10 mol/L in Dulbecco's Modified Eagle Medium (D6546 Sigma-Aldrich, Dorset, UK) before its addition to cell cultures. For oligomerization, the stock solution was diluted to 300 mol/L in Dulbecco's Modified Eagle Medium and incubated overnight at 37°C. We previously showed that this leads to formation of a mixture of trimeric, tetrameric and higher molecular weight species of A␤ . 23 Immediately before its addition to cell cultures, the oligomeric A␤ 1-42 was further diluted to 10 mol/L in Dulbecco's Modified Eagle Medium.
Cell Culture and cDNA Generation for RT-PCR
SH-SY5Y human neuroblastoma cells (European Collection of Cell Cultures, Porton Down, UK) were grown in Dulbecco's Modified Eagle Medium supplemented with 2 mmol/L L-glutamine (Sigma-Aldrich) and 15% fetal calf serum (Autogen Bioclear, Wiltshire, UK) at 37°C in 5%CO 2 /95% air. The cells were differentiated in 10 mol/L retinoic acid (Sigma-Aldrich) for 6 days and treated with 10 mol/L monomeric or 10 mol/L oligomeric A␤ 1-42 for 4 and 24 hours. Control cells were incubated for the same duration in Dulbecco's Modified Eagle Medium supplemented with 0.2% acetonitrile. Following treatment, protein and RNA were extracted from the cells.
RNA was extracted and cDNA produced using the TaqMan gene expression cells-Ct-kit (Applied Biosystems) according to the manufacturer's instructions. 10 3 cells were added to lysis solution plus DNase I (5 minutes) before the addition of the stop solution (2 minutes). To synthesize cDNA, the extracted RNA was placed in a thermal cycler with the reverse transcription buffer and RT enzyme mix and incubated at 37°C for 1 hour and 95°C for 5 minutes. The cDNA concentration was measured and RT-PCR was performed as described previously, with GAPDH as housekeeping gene.
Statistical Analysis
The relationship between simulated PM delay and ECE-2 concentration was assessed by Pearson correlation analysis. Comparisons of ECE-2 mRNA and protein levels between the AD, VaD, and control groups were made by Dunn's multiple comparison test. Wilcoxon signed rank test was used to compare ECE-2 mRNA levels in SH-SY5Y 
Results
Distribution of ECE-2 in Human Temporal Neocortex
Pyramidal neurons in the hippocampus in AD, VaD, and control brains were strongly immunopositive for ECE-2 ( Figure 1, A-H) . The pattern of immunolabeling was similar for the two antibodies. The neurons showed a combination of finely granular and diffuse labeling of the somatic cytoplasm. Scattered astrocytes and possibly microglia contained coarsely granular immunopositive cytoplasmic material; this was particularly prominent in the AD brains. Pyramidal neurons and scattered astrocytes and microglia (including some perivascular microglia) were also immunopositive for ECE-2 within the neocortex, but the staining tended to be weaker than that in the hippocampus. A few leptomeningeal arteries showed very weak ECE-2 positivity in the tunica media but most blood vessels were not labeled. However, most intracortical blood vessels were close to ECE-2 positive neurons.
Measurement of ECE-2 mRNA in Human Temporal Neocortex
ECE-2 mRNA levels differed significantly between AD, VaD, and control brains (Figure 2) . Calibration of ECE-2 mRNA levels with reference to GAPDH revealed an approximately threefold increase in temporal neocortex from AD, as compared with normal controls (P ϭ 0.01). ECE-2 mRNA levels were not significantly increased in the VaD brains.
GAPDH is often used as the housekeeping gene for RT-PCR, as it is expressed in all cell types. However, because of this fact, it may not be an accurate calibrator when measuring RNA levels within neurons in diseased brain tissue, as increases in the number of GAPDHexpressing non-neuronal cells, particularly astrocytes and microglia, may mask changes in expression of the gene of interest by neurons. As ECE-2 is predominantly expressed in neurons, we therefore also analyzed ECE-2 mRNA levels with respect to two other neuron-specific transcripts: neuron-specific enolase and microtubule-associated protein-2. Calculations based on use of neuronspecific enolase and microtubule-associated protein-2 mRNA levels as calibrators indicated approximately ninefold (P Ͻ 0.001) and an approximately sixfold (P ϭ 0.01) increases respectively, in ECE-2 mRNA levels in AD compared to control temporal neocortex. Use of these calibrators indicated no increase in ECE-2 mRNA in VaD.
ECE-2 Protein Levels in Human Temporal Neocortex
ECE-2 protein level was significantly higher in temporal neocortex from AD than control (P Ͻ 0.001) brains (Figure 3) . The mean concentration in AD brains was 108.9 ng/ml (SD ϭ 53.5), in VaD brains 74.3 ng/ml (SD ϭ 39.4) and controls 42.2 ng/ml (SD ϭ 29.2). The difference between ECE-2 protein level in VaD and control brains was not significant.
Simulated Effects of Post-Mortem Delay on Stability of ECE-2
When we measured ECE-2 level in brain tissue that had been stored at different times and temperatures, we found no significant change over periods of up to 72 hours, either at room temperature or 4°C (see supplementary Figure S1 available at http://ajp.amjpathol.org). It is therefore unlikely that differences in ECE-2 protein measurements were due to differences in postmortem delay.
Expression of ECE-2 mRNA Following Exposure of SH-SY5Y Cells to A␤
To investigate whether the increase in ECE-2 in AD was a response to the accumulation of A␤, we measured ECE-2 mRNA expression after 4 hours and 24 hours treatment of SH-SY5Y cells with monomeric or oligomeric A␤ 1-42 , compared to non-treated cells. There was a decrease in ECE-2 mRNA levels after 4 hours treatment with either monomeric (P ϭ 0.0002) or oligomeric A␤ (P Ͻ 0.0001), and an increase in ECE-2 mRNA levels after 24 hours treatment with monomeric (P ϭ 0.0023) or oligomeric A␤ (P ϭ 0.0037) (Figure 4) . Ϫ⌬⌬Ct method, with GAPDH, neuron-specific enolase, and microtubule-associated protein-2 as calibrators. The geometric mean and 95% confidence intervals are shown for each group on a logarithmic scale (to the base 2). The ECE-2 mRNA level is significantly elevated in AD but not VaD. 
Discussion
Although ECE-2 has been shown to be a physiologically relevant A␤-degrading enzyme in mouse models, 17, 18 as far as we are aware, this is the first investigation of ECE-2 protein in AD and only a single previous study has been reported of ECE-2 mRNA in AD. 20 We have now shown that ECE-2 mRNA and protein levels are markedly elevated in the temporal neocortex in AD but not VaD, indicating that the increased expression of ECE-2 in AD is unlikely to be simply secondary to tissue damage. Our in vitro findings of a significant increase in ECE-2 mRNA expression after 24 hours treatment of SH-SY5Y cells with both monomeric A␤ and oligomeric A␤ 1-42 supports our findings of increased ECE-2 in AD, suggesting that ECE-2 gene expression is up-regulated in response to A␤. The decrease in ECE-2 mRNA expression after 4 hours treatment with A␤ 42 could indicate a delay in the response to A␤, however this apparent feedback mechanism is unknown, and warrants further investigation.
Our findings differ from those of Weeraratna et al 20 who found a decrease in ECE-2 mRNA in inferior parietal cortex in AD. However, the studies are not directly comparable. Unlike Weeraratna et al, 20 we examined temporal cortex. Our sample size was higher (14 AD cases and 15 controls, as compared with 6 AD cases and 6 controls). In addition, it is unclear from their paper how the data were calibrated with respect to housekeeping/reference gene expression. Immunohistochemistry was only performed on one case, and no data were presented as to the specificity of the antibody to ECE-2.
Multiple proteolytic enzymes have the capacity to degrade A␤, but their relative contributions to A␤ degradation in vivo are not known. Present findings indicate that A␤ accumulation is not likely to be caused by ECE-2 deficiency. Previous studies have shown the expression of some other putative A␤-degrading enzymes to be decreased in AD. Immunolabeling of insulin-degrading enzyme (IDE) was reduced in hippocampal neurons 24 and labeling of neprilysin (NEP) was reduced in cerebrocortical neurons and blood vessels. [25] [26] [27] Other studies have found lower NEP mRNA levels 25, 28 and lower IDE mRNA, protein levels, and enzyme activity in AD. 29 -31 However, these findings cannot be construed as evidence of a primary deficiency in the expression of either NEP or IDE. None of these studies has adjusted for the potential impact of neuronal loss or damage in established AD, or for the possible effects of other processes such as microglial inflammation or astrocytosis, and the studies have mostly been of relatively small cohorts. Western blot analysis of NEP in human brain tissue homogenates has yielded inconsistent results: some studies have shown a reduction of NEP in AD 28, 32 and others have shown no significant change. 27, 33, 34 Recently, Vepsalainen et al 35 reported that IDE mRNA and protein levels were significantly higher in APPswe/ PSEN(dE9) mice than in non-transgenic littermates. NEP protein levels were also higher, but this did not reach statistical significance. The positive correlation between IDE mRNA and levels of A␤ and A␤ suggested that IDE mRNA production might be induced by A␤, possibly in activated astrocytes as a result of A␤-related inflammation. 36 Similarly, up-regulation of NEP has been shown in activated astrocytes surrounding plaques. 36, 37 Other studies have examined the effect on several A␤-degrading enzymes of incubating neuronal, glial, or smooth muscle cell lines with fibrillar A␤ 42 in vitro. This was shown to up-regulate IDE, 36 MMP-2, -3, and -9, 38 -40 and plasminogen activators. 41 Our in vitro data provide evidence that the up-regulation of ECE-2 expression is similarly likely to be caused by the accumulation of A␤ in AD, perhaps as a physiological feedback response or protective mechanism whereby increased A␤ degradation minimizes further A␤ accumulation.
Several lines of evidence suggest that intracerebral accumulation of A␤ has the potential to produce cerebrovascular dysfunction. Synthetic A␤ has been shown to impair endothelium-dependent relaxation and enhance vasoconstriction in vivo and in vitro. [42] [43] [44] Cerebral blood flow is reduced by 20% to 40% in mice that over-express APP 45 and regulation of cerebral blood flow tends to be most impaired in transgenic mice with highest intracerebral levels of A␤. 46 It has long been speculated that cerebrovascular dysfunction contributes to AD. 47 Patients with AD have reduced cerebral blood flow, 48 and cerebral blood flow correlates inversely with performance of AD patients upon minimental state examination. 49 -51 Impairment of cerebrovascular autoregulation precedes neuropathological alterations in APP transgenic mice, supporting the hypothesis that reduced cerebral perfusion may play a pathogenic role in AD. 46 ET-1 plays a central role in the regulation of blood flow. It is produced by ECE-mediated cleavage of big ET-1. ET-1 can act on ET A receptors to cause vasoconstriction and ET B receptors to cause vasodilatation. 52 Intravenous administration of ET-1 in different species leads to a short-lived decrease in vascular resistance (ie, vasodilation), followed by a long-term increase (ie, vasoconstriction). 53 The overall physiological effect of ET-1 is to increase blood pressure 54 by an increase in vascular tone. 55 Endothelin is the major vasoconstrictor in cerebral blood vessels and can induce marked and sustained cerebral vasoconstriction. 56 A␤ 1-40 and A␤ were shown to enhance ET-1 induced vasoconstriction in rat aorta. 57 An increase in ECE-2 may be a mechanism through which A␤ accumulation affects cerebrovascular blood flow and the capacity of the central nervous system to increase blood flow in response to regional increases in metabolic demand. Increased A␤ in AD may induce ECE-2 expression, proteolytic cleavage of big-ET-1 and release of ET-1, including by perivascular nerve terminals, with the result that cerebrovascular tone is increased and blood flow is reduced. This raises the possibility that endothelin-1 receptor antagonists, already licensed for the treatment of other diseases such as pulmonary hypertension, could be of benefit in AD, as a way to counteract overproduction of ET-1 and to increase cerebral perfusion.
